Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ASCO 2023
ASCO 2023
ASCO in Review: Oncologists See Practice-Changing, Affirming Data
BioSpace
Thu, 06/8/23 - 09:26 pm
ASCO 2023
oncologists
cancer
AstraZeneca
Tagrisso
non-small cell lung cancer
Novartis
Kisqali
breast cancer
Merck
Keytruda
Moderna Therapeutics
cancer vaccine
ASCO 2023 – Novocure sinks as Lunar’s limitations become clear
EP Vantage
Thu, 06/8/23 - 09:46 am
ASCO 2023
Novocure
tumor treating fields
ASCO 2023 – early first-line lung cancer data mined for datopotamab gold
EP Vantage
Wed, 06/7/23 - 10:02 am
ASCO 2023
Daiichi Sankyo
AstraZeneca
datopotamab deruxtecan
non-small cell lung cancer
ASCO: Merck's Keytruda trips in EGFR lung cancer as Roche's Tecentriq fails in kidney cancer
Fierce Pharma
Tue, 06/6/23 - 04:19 pm
ASCO 2023
Merck
Keytruda
EGFR lung cancer
Roche
Tecentriq
kidney cancer
ASCO 2023: Precigen reports positive early data for CAR-T therapy
BioSpace
Tue, 06/6/23 - 11:12 am
ASCO 2023
Precigen
CAR-T
PRGN-3005
ovarian cancer
Kite's Yescarta CAR T-cell Therapy Shows Extended Survival in Relapsed/Refractory Large B-cell Lymphoma
Businesswire
Tue, 06/6/23 - 10:11 am
ASCO 2023
Gilead Sciences
Kite Pharma
Yescarta
relapsed or refractory large B-cell lymphoma
ASCO 2023: AstraZeneca’s PD-1/TIGIT shows promise in checkpoint-exposed NSCLC
Clinical Trials Arena
Tue, 06/6/23 - 10:06 am
ASCO 2023
AstraZeneca
clinical trials
non-small cell lung cancer
rilvegostomig
Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data
Yahoo/Reuters
Tue, 06/6/23 - 10:04 am
ASCO 2023
Merck
Moderna Therapeutics
MRNA
vaccines
skin cancer
ASCO: Johnson & Johnson's Balversa tops chemotherapy in bladder cancer trial
Fierce Pharma
Mon, 06/5/23 - 10:02 pm
ASCO 2023
JNJ
Balversa
bladder cancer
ASCO: French Pharma's Drug Slows Tumors in Brain Cancer Patients
BioSpace
Mon, 06/5/23 - 10:00 pm
ASCO 2023
Servier
glioma
vorasidenib
ASCO: AstraZeneca Posts Strong Survival Data for Tagrisso in NSCLC Patients
BioSpace
Mon, 06/5/23 - 09:59 pm
ASCO 2023
AstraZeneca
Tagrisso
non-small cell lung cancer
AstraZeneca study points to new uses for targeted cancer drug Enhertu
BioPharma Dive
Mon, 06/5/23 - 11:32 am
ASCO 2023
AstraZeneca
Enhertu
uterine cancer
cervical cancer
ovarian cancer
bladder cancer
ASCO: Affimed pivots to cancer combo after failing to meet monotherapy study continuation criteria
Fierce Biotech
Mon, 06/5/23 - 10:20 am
Affimed
ASCO 2023
AFM24
J&J sees trial data supporting earlier CAR-T use in multiple myeloma
BioPharma Dive
Mon, 06/5/23 - 10:12 am
ASCO 2023
JNJ
Legend Biotech
Carvykti
CAR-T
Multiple Myeloma
ASCO 2023 – Bicara eyes head and neck niche
EP Vantage
Mon, 06/5/23 - 09:59 am
ASCO 2023
Bicara Therapeutics
BCA101
head and neck cancer
ASCO: Gilead and Arcus's Cancer Immunotherapy Combo Faces Scrutiny Over Lower Survival Rates
BioSpace
Sun, 06/4/23 - 04:27 pm
ASCO 2023
Gilead Sciences
Arcus Biosciences
anti-TIGIT
non-small cell lung cancer
domvanalimab
ASCO: AstraZeneca guns for wider ovarian cancer market with Imfinzi-Lynparza combo. Will the FDA buy the plan?
Fierce Pharma
Sun, 06/4/23 - 04:24 pm
ASCO 2023
AstraZeneca
Lynparza
Imfinzi
ovarian cancer
ASCO: Merck bills Keytruda, used around surgery, as new standard in 'messy' early lung cancer realm
Fierce Pharma
Sun, 06/4/23 - 04:22 pm
ASCO 2023
Merck
Keytruda
non-small cell lung cancer
Merck and Eisai tease results for renal carcinoma treatment
Clinical Trials Arena
Tue, 05/30/23 - 09:18 pm
Merck
Eisai
ASCO 2023
Lenvima
Keytruda
renal cell carcinoma
Hummingbird Bioscience Announces HMBD-002 Trials in Progress Poster at ASCO Annual Meeting 2023
BioSpace
Tue, 05/30/23 - 09:47 am
Hummingbird Biosciences
HMBD-002
cliincal trials
ASCO 2023
triple-negative breast cancer
non-small cell lung cancer
Pages
1
2
next ›
last »